Prediction of CYP3A4-mediated drug-drug interactions of a novel Bcl-2 inhibitor TQB3909 using physiologically based pharmacokinetic modeling
Cancer Chemotherapy and Pharmacology · 2025
DOI: 10.1007/s00280-025-04838-w ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Chemotherapy and Pharmacology, 2025. Verfasst von Hui Chen und 7 weiteren Autor:innen. Beteiligte Einrichtung: Chia Tai Tianqing Pharmaceutical Group Co., Ltd, Fuying Road 1099, 211100, Nanjing, China. Hauptthemen laut MEDLINE: Cytochrome P-450 CYP3A, Cytochrome P-450 CYP3A Inhibitors, Models, Biological. Die Arbeit nennt 29 Literaturangaben. Gefördert von: Chia Tai Tianqing Pharmaceutical Group Co., Ltd,.
Abstract (Originalsprache)
PURPOSE: This study aimed to establish a physiologically based pharmacokinetic (PBPK) model of TQB3909 and predict the CYP3A4-mediated drug-drug interactions (DDIs) of TQB3909 to inform dosing recommendations in patients. METHODS: PBPK model was developed by integrating the physicochemical properties, in vivo and in vitro metabolic parameters of TQB3909, along with phase I clinical pharmacokinetic data and DDI clinical trial data. RESULTS: Model verification showed that the simulated drug concentrations by established PBPK model were fitted well with clinical data, with a mean fold error (MFE) ≤ 2 and most of predicted Cmax and AUC were within the range of 2-fold boundaries compared to the clinical data. Predicted Cmax and AUC geometric mean ratios (GMRs) of TQB3909 with strong CYP3A4 inhibitor itraconazole or inducer rifampicin were within 0.8 to 1.25-fold range of the observed data. DDI simulations showed that co-administration with verapamil, a moderate CYP3A4 inhibitor, increased the exposure of TQB3909 by 26%, whereas co-administration with efavirenz, a moderate CYP3A4 inducer, decreased TQB3909 exposure to 53.8% of baseline. No obvious effect of fluvoxamine (a weak CYP3A4 inhibitor) was found. CONCLUSION: This developed PBPK model effectively simulated the impact of CYP3A4 perpetrators on the pharmacokinetic behavior of TQB3909 in humans, informing clinical dose adjustment of TQB3909.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd, Fuying Road 1099, 211100, Nanjing, China.
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd, Fuying Road 1099, 211100, Nanjing, China. cpu_wangxin@163.com.
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd, Fuying Road 1099, 211100, Nanjing, China. ding.yu@cttq.com.
Förderung
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd,
Zitieren
APA
Chen, H., Zhu, S., Yang, A., Li, X., Wang, X., Zhao, W., Wang, X., & Yu, D. (2025). Prediction of CYP3A4-mediated drug-drug interactions of a novel Bcl-2 inhibitor TQB3909 using physiologically based pharmacokinetic modeling. Cancer Chemotherapy and Pharmacology. https://doi.org/10.1007/s00280-025-04838-w
Vancouver
Chen H, Zhu S, Yang A, Li X, Wang X, Zhao W, et al. Prediction of CYP3A4-mediated drug-drug interactions of a novel Bcl-2 inhibitor TQB3909 using physiologically based pharmacokinetic modeling. Cancer Chemotherapy and Pharmacology. 2025. doi:10.1007/s00280-025-04838-w
BibTeX
@article{Chen2025,
author = {Chen, Hui and Zhu, Shixing and Yang, Anqi and Li, Xu and Wang, Xunqiang and Zhao, Wei and Wang, Xin and Yu, Ding},
title = {Prediction of CYP3A4-mediated drug-drug interactions of a novel Bcl-2 inhibitor TQB3909 using physiologically based pharmacokinetic modeling},
journal = {Cancer Chemotherapy and Pharmacology},
year = {2025},
doi = {10.1007/s00280-025-04838-w}
}
EUVIMED